Arvinas secures VEPPANU approval for breast cancer, extends cash runway into 2028

Arvinas (NASDAQ:ARVN) reported that the U.S. Food and Drug Administration has approved VEPPANU (vepdegestrant) for the treatment of patients with ESR1-mutated ER+/HER2- advanced breast cancer.

The decision validates Arvinas’ proprietary protein degradation platform, which utilizes the body's own natural protein disposal system to eliminate disease-causing proteins.

To accelerate its commercial footprint, the company also entered into a global licensing agreement with Rigel Pharmaceuticals, further expanding the potential reach of its oncology and neurology pipelines.

Financially, Arvinas reported first-quarter revenue of $15.6 million, compared to $188.8 million in the prior-year period.

The year-over-year decrease is primarily attributed to the timing of collaboration revenue recognized from its ongoing strategic partnership with Pfizer.

However, the company demonstrated increased fiscal discipline, with GAAP research and development expenses narrowing to $60.3 million from $90.8 million, and general and administrative expenses falling to $19.1 million.

Arvinas ended the quarter with $614.9 million in cash and marketable securities, a liquidity position the company expects will fund operations through the second half of 2028.

In addition to the VEPPANU approval, the company highlighted promising new data from its neurology segment.

Initial Phase 1 biomarker results for ARV-102 showed significant target engagement, supporting the further development of the candidate for neurodegenerative diseases.

The quarter also marked a pivotal change in corporate governance, with the appointment of Randy Teel as President and Chief Executive Officer.

Teel, who previously served as the company's interim CEO, is tasked with overseeing the commercial launch of VEPPANU and the clinical acceleration of the company's second-generation degrader assets.